CD33 and acute myeloid leukemia: SG-CD33A, a novel CD33 targeting ADC with a pyrolobenzodiapine dimer and using site specific conjugation with engineered cysteines has recently entered Phase 1 trials in AML patients and it will be interesting to see the pharmacokinetic and safety profiles of this ADC with a novel cytotoxin and linker (36,37).